Jeena Sikho Lifecare: FY26 Results — 71% Revenue Jump on a Trebling Profit

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Jeena Sikho Lifecare (JSLL) served up FY26 numbers that made the sector’s growth memes look tame: revenue jumped 71% to ₹801 Cr; net profit scaled 178% to ₹222 Cr. The market prices this at 34x reported earnings—tied with its own 5-year average multiple of 47x (down from peak disgrace).

The tension: raw profit scaling faster than revenue looks like operating leverage, but one-time provisions (~₹21 Cr) masked the floor. The cash flow from operations hit ₹262 Cr against capex of ₹211 Cr, leaving free cash positive.

IPD volumes climbed 65% to 40,454 patients; OPD volumes 69% to 5.7 lakh. The hospital bed count sits at 2,300 with another 445 in pipeline—capacity already baked in for next two years. Occupancy remains the dial to watch.

Management expects ₹3,000 Cr revenue in 3–5 years and ₹300 Cr minimum PAT in FY27. That’s a 275% profit jump on a 275% revenue jump. Either the spreadsheet works, or the boil-down gets harder.

2. Introduction

Ten years ago, Acharya Manish Ji founded Jeena Sikho with a bet on ancient Ayurveda winning the modern health anxiety narrative. The company went public in April 2022 on the NSE, then migrated to the mainboard in August 2025 after proving numbers scaled faster than board membership rules allowed.

JSLL operates 61 hospitals and 58 clinics/daycare centres across 23 states and 100+ cities. Only 33 are franchised; the rest are company-run or payroll-locked, a model designed to lock patient flow into products.

The business splits 48:52 between services and products—deliberate, recurring, synergistic. Services (₹385 Cr in FY26) anchor volume and pricing power; products (₹416 Cr) supply the durable, high-margin tail.

Last quarter, management flagged a ₹21 Cr pile of provisions: labour code amendments, ESOP costs, performance bonuses, lease adjustments under the new auditor (Grant Thornton, first year). These are real money out, but management argues they don’t repeat at this scale. Read that carefully.

Government business dropped from ₹118 Cr to ₹36 Cr on purpose—the sector hates government payment terms. Private and retail sales grew to offset: from ₹136 Cr + ₹215 Cr to ₹349 Cr + ₹415 Cr. The flywheel, not a pivot.

3. Business Model: WTF Do They Even Do?

JSLL runs what it calls a hub-and-spoke Ayurveda network. Clinics feed patients into hospitals; hospitals feed patients back to products; products customers call support, convert to IPD cases, buy more products.

The services arm delivers Panchakarma therapies (the ayurvedic deep-clean), IPD (inpatient), OPD (outpatient), and 72-hour camps that convert 30% of attendees into paying patients at ₹30–60 lakh per camp. Camps are explicitly profit centers, not marketing spend.

The products arm: 330+ SKUs across immunity, pain, organs (kidney/liver/thyroid), weight loss, and OTC launches just starting. Gross margins exceed 85%; manufacturing is outsourced; distribution runs through company call centers, e-commerce, and now retail pharmacy shelves.

A 100-bed facility costs ₹3–4 lakh per bed to set up (₹300–400 lakh total), breaks even at 35% occupancy, and hits payback in <6 months at decent utilization. The CFO claims capital-light; the balance sheet agrees. ROCE at 46% (3-year average) sits in the 70% orbit management claims only when you annualize good quarters.

What makes it work: repeat. Hospital IPD patients are 26% repeat; product customers are 34% repeat. That’s not trial; that’s behavior. Word-of-mouth supplants paid marketing—the company runs social media and TV, but it measures success by patient camps drawing 100–120 visitors per quarter.

4. Financials Overview

Figures are consolidated, in ₹ crore.

Recent Quarterly Performance

Q4 delivered ₹216 Cr revenue, up 55% YoY, but QoQ softness of 3% came with a 23% EBITDA dip. Management blamed geopolitical jitters (Trump-Iran narrative) deferring discretionary preventive visits; separately, the company stopped booking advances as revenue post-Grant Thornton audit, shifting timing between quarters. One-time provisions hit ₹21 Cr (~INR 7 Cr labour/ESOP, ~INR 5 Cr ECL, ~INR 9 Cr lease provisions). Adding back half of that suggests EBITDA margin runs closer to 46% ex-noise.

Full-Year FY26 vs FY25

FY26 EBITDA margin jumped 1,400 basis points to 44%, driven by operational leverage (fixed clinic/hospital footprint absorbing 71% higher revenue) and products’ recurring gross margin (85%+). PAT jumped 177% to ₹222 Cr on 178% earnings-per-share growth.

Balance Sheet Shape

The balance sheet flipped. FY25 showed ₹11 Cr borrowings; FY26 shows ₹127 Cr. This is not debt creep—it’s structured investment. Cash from operations was ₹262 Cr; capex consumed ₹211 Cr. The company borrowed to fund growth, not plug holes.

Management claims “absolutely no debt” in the FY26 call, a claim auditors would dispute (₹127 Cr sits on the sheet). The distinction likely hinges on purpose: if borrowings funded imminent hospital capex, management sees it as good leverage (ROCE 71% > cost of debt); if it’s floating liability, it’s debt.

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

The market currently pays 34.2x earnings, below JSLL’s own 5-year average of 46.8x. Peer median P/E is 32.2x (sector comparison: Sun Pharma 34.8x, Torrent 70.6x, Lupin 18.2x—JSLL overlaps high-end growth but sits below trough peers). ROE at 60% towers over the peer median of 12.5%; ROCE of 70.7% is roughly 4–5x median 15%. This suggests the market is pricing in growth (JSLL’s 3-year revenue CAGR 58% vs peer 10–20%) but remains skeptical on durability or margin compression risk.

The multiple appears to be calibrated on: (a) Ayurveda remaining a niche (no mainstream adoption tailwind), (b) Occupancy risk (51% current vs stated 35% break-even—thin buffer), and (c) Product mix stability (IPD and OPD volumes volatile quarter-to-quarter, as Q4 proved). Management’s ambition to hit ₹3,000 Cr revenue in 3–5 years would imply a 3–4x multiple compression at constant P/E, or a re-rating upward if margins hold.

6. What’s Cooking

Mathura hospital opened June 10. 100 operational beds, announced weeks ago, now live.

Lucknow expansion finalizing this week. 160+ bed hospital, ₹3 Cr capex, target August 2026 opening.

Ayodhya day-care announced. 50 lakh investment, August 2026 target. Captures pilgrim traffic + Yogi Adityanath’s UP push into Ayurveda empanelment (UPSS scheme, Ayushman-related programs).

Insurance mix jumped to 26% of sales (from 4% prior). Management met HDFC ERGO, positioning Ayurveda as pre-surgery cost-reduction. If insurance companies make Ayurveda the default preventive step before paying ₹2 lakh+ orthopedic bills, unit economics flip sharply.

OTC product launches accelerated. 9 products in <3 months. BP/sugar/kidney/liver/depression pills now targeted for June–July launch. Pet health kits, pregnancy products, plant-based protein in the pipeline. Only one product (green box) older than Q4.

Swadeshi Health Card went live in Q4. Loyalty scheme: referral benefits, diagnostic discounts, integrated ecosystem play. Management provisioned ₹1.25 Cr for loyalty points; CFO called it trial phase. Repeat rate data suggests loyalty already exists (34% product repeat, 26% IPD). This formalizes and monetizes it.

Camp volumes held steady. Q4 FY26 saw 72-hour camps with 431 cumulative visitors; average 30% conversion; ₹30–60 lakh direct business per camp. Camps cost near-zero (just staff), making them a true funnel with 10–15% margins.

7. Balance Sheet

Assets doubled from FY25 to FY26, driven by ₹307 Cr net PP&E (up from ₹153 Cr), ₹95 Cr investments (mostly goodwill on acqui-hires or restricted cash), and working capital. Liabilities grew proportionally. Equity grew 82% to ₹467 Cr (up from ₹256 Cr), funded by retained earnings (₹222 Cr net profit in FY26 minus ₹56 Cr dividend = ₹166 Cr retained).

The ₹127 Cr borrowing jump is the headline. At IPO, the company had ₹0.54 Cr debt; post-IPO, it cruised near debt-free. The new borrowings likely funded the Meerut (315 bed) and Navi Mumbai (145 bed) hospital capex, plus the Panchkula and Manesar expansions. If ROCE holds at 71%, the leverage is benign. If occupancy drops to 25%, it becomes a pressure point.

Cash sits at ₹108 Cr, up from ₹26 Cr in FY25. That’s 4 months of operating expense; healthy, not bloated.

Three roasts:

Management talks of “debt-free” operations despite ₹127 Cr on the balance sheet—linguistic hair-splitting if the debt funded asset expansion, but a red flag if it’s floating liability.

Other assets of ₹269 Cr (up from ₹159 Cr) are mostly receivables and restricted deposits. Transparency here is fuzzy; the auditor (new firm) may tighten definitions year-on-year.

Trade receivables fell from ₹97.63 Cr (FY25) to ₹69.93 Cr (FY26), despite 71% higher sales. This is the win—debtor days compressed from 76 (FY25) to 32 (FY26). Insurance payouts and government panels now settle faster (or insurance mix skew helped). Don’t assume this repeats; government payment risk is real.

One wisdom line: A balance sheet with nothing to hide yet nothing to brag about—clean equity, borrowed growth at fair rates, and receivables that suddenly behave. The next stress test is occupancy, not leverage.

8. Cash Flow: Sab Number Game Hai

Operating cash flow hit ₹262 Cr in FY26, up 282% from ₹69 Cr in FY25. The jump is real—higher earnings, tighter receivables, and deferred payables. Capex (net of inflows) was ₹211 Cr, leaving free cash of ₹51 Cr. The company paid ₹59 Cr in financing (mostly dividend payout).

The trajectory is clean: operating leverage is generating cash fast enough to fund growth and return capital. If revenue hits ₹1,200 Cr in three years, operating cash could breach ₹1,000 Cr, turning JSLL into a regional cash cow. If occupancy peaks at 51%, operating cash flattens and capex becomes a drag.

One wisdom line: Cash flow today reflects a young business still in high-utilization growth; it will compress sharply if growth slows, because fixed costs (payroll, rent) don’t scale down with patients.

9. Ratios: Sexy or Stressy?

ROE of 60% means the company is earning ₹60 for every ₹100 of shareholder equity. That’s phenomenal—far above peer median of 12.5%, far above required return thresholds. Caveat: equity base is small (₹467 Cr) and growing fast (₹166 Cr retained earnings in one year). The denominator inflates easily in a growth company.

ROCE of 70.7% reflects invested capital generating returns at that multiple. ROCE = NOPAT / Invested Capital. NOPAT (net operating profit after tax) was ~₹225 Cr (₹222 Cr net profit + ₹13 Cr interest on debt post-tax); invested capital is ₹639 Cr (equity + net debt). The ratio is exceptional—far above peer median of 15.1%. But ROCE inflates when new capex hasn’t cooled to steady-state, because capex year 1 rarely returns full ROCE. As hospitals mature (occupancy 51% → 70%), ROCE should rise further.

P/E of 34.2 on a 178% earnings growth year is cheap. The market pays 34x for a company growing earnings at 177% YoY? That should command 50x+. Either (a) the market fears the growth is unsustainable (fair, given quarter-to-quarter volatility), or (b) investors are under-exposed to Ayurveda plays and underpricing the category. The gap exists; interpretation is personal.

PAT Margin of 28% is world-class for a services/products hybrid. Most hospital chains (Apollo, Fortis) run 10–15%. JSLL’s margin comes from (a) asset-light franchises (no hospital depreciation tax on franchisee), (b) product tail (85%+ gross margin), and (c) operating leverage (fixed clinic footprint absorbing 71% higher sales).

Debt-to-Equity of 0.27 is relaxed. The leverage is there (₹127 Cr debt on ₹467 Cr equity), but it’s not oppressive. At ROCE 71% and cost of debt ~8–10% (estimated), the spread is fat.

Observations (not judgments):

ROE 60% is strong, but ROCE inflation risk lurks: once capex completes and hospitals mature, returns will compress naturally. Don’t assume 60% ROE for three more years.

P/E 34x on earnings growth of 177% leaves no margin for narrative to crack. If FY27 earnings growth slows to 40%, the multiple re-rates hard.

Debt-to-Equity 0.27 is safe. But ₹127 Cr of new borrowing in one year is abnormal. That pace of leverage can’t sustain; at some point, the company refinances or caps capex.

10. P&L Breakdown: Show Me the Money

Revenue grew 44% (FY24 → FY25) then 71% (FY25 → FY26). The acceleration is real: capacity additions (Meerut, Lucknow, Navi Mumbai, Panchkula, Manesar) ramped from 2024 onward, hitting peak occupancy run-rate in FY26. IPD volumes grew 65% YoY; OPD 69%. The growth is broad, not one-off.

EBITDA margins improved from 29% (FY24) to 30% (FY25) to 44% (FY26). The 1,400 bps jump in one year is exceptional. Management claims ₹21 Cr of one-time provisions dragged FY26, implying “true” EBITDA margin closer to 46%. Even so, the operating leverage is real: clinics and hub infrastructure are mostly fixed costs, so each patient dollar dropped on a near-full cost base.

PAT grew from ₹69 Cr (FY24) to ₹91 Cr (FY25) to ₹222 Cr (FY26)—a 3x scaling in two years. Interest costs rose from ₹0.4 Cr (FY24) to ₹1.1 Cr (FY25) to ₹12.8 Cr (FY26) due to new borrowing, but EBITDA scaling outpaced it. Tax kept steady at ~25%.

The trajectory tells a coherent story: capacity investments made in FY24–FY25 hit utilization run-rate in FY26. If occupancy stabilizes at 51% going forward, EBITDA margin will plateau around 42–44%. If occupancy climbs to 65% (peer typical), margin could touch 50%. If it stays at 30% (pre-FY26 average), margin compresses to 35%.

11. Peer Comparison

JSLL is dwarfed by the pharma cohort—Sun Pharma is ₹58,000 Cr vs JSLL at ₹801 Cr. But JSLL’s growth (71% YoY) outpaces every peer in this table (Sun Pharma 12%, Lupin 32%, Cipla -2% YoY). P/E at 34x sits between Cipla’s 29.5x and Sun Pharma’s 34.8x—no discount for being smaller. The market pays the same multiple for JSLL as for a 70-year-old pharma incumbent. ROCE at 70.7% is 3.5x the median. Either JSLL’s returns are unsustainably high, or the peer set’s returns are depressed by over-capacity.

Facts without judgment: JSLL is 1/50th the size of Sun Pharma but growing 6x faster. Peer comparison here hinges on whether you believe Ayurveda as a category can sustain 60%+ growth for three more years. The data says yes today; the market is less sure.

12. Miscellaneous: Shareholding & Promoters

Manish Grover and spouse Bhavna hold 63.27% combined—a tight grip. Bhavna’s stake dropped from 0.85% to 0.20% in late FY25, likely a domestic tax-planning shuffle. Other family members (Rohit, Shreya, Sahil) hold minor stakes and board seats. Shreya was re-designated whole-time director in September 2025.

FII/DII holding stands at 6.8%, up from 2% in late FY24. Sixteenth Street Asian Gems Fund is the only named FII (5.66%). This tells you FIIs are dabbling, not bullish—large positions would suggest conviction in the Ayurveda narrative.

Public holding at 29.77% is solid liquidity; retail ownership is real. No red flags.

Promoter roast (on conduct/history, not on trustworthiness to shareholders): Acharya Manish Ji is a polarizing figure—he claims credit for Nobel Prize concepts (Seed & Soil, Autophagy, Circadian Rhythms) without conducting the research, and deploys quasi-spiritual framing (“अपना डॉक्टर खुद बनो,” “Heal in India”) in marketing materials that border on messianic. His social media channels (YouTube 1.24M, Facebook 3M, Instagram 1.8M) are personality cults, not corporate comms. The company’s success hinges partly on his brand authority; if he were to step down or lose credibility, investor confidence could crack sharply. The board is light on independent directors (three: Nanak Chand CFO, Smita Chaturvedi, Karanvir Singh Bindra). Oversight exists, but concentration risk is high.

13. Corporate Governance: Angels or Devils?

Auditors: Grant Thornton took over in FY26, first audit. Prior auditors (unnamed in documents) signed off on smaller bases. Grant Thornton introduced stricter Ind AS accounting, leading to ₹9 Cr of lease-related provisions and ₹5 Cr of ECL (expected credit loss) provisions in Q4. These are not errors; they’re tightening of standards. The shift delayed FY26 results publication past typical timelines—a minor red flag for process, not substance.

Board: 9 directors total. 3 independent. Manish Grover (MD) has ultimate decision-making; CFO Nanak Chand is a KMP (key managerial person). Board meetings happen, dividend is consistent (₹1.10 per share recommended for FY26), and audit committee is chaired by an independent. Process is intact.

Related-Party Transactions: Management did not disclose material related-party transactions in available documents. Promotional family members hold minor stakes and do not appear to have significant supply contracts or rental relationships flagged.

Pledges: Promoter pledge percentage stands at 0.00% as of March 2026. No collateral lock-in risk visible.

Resignations, Tax Demands, Credit Actions: None flagged in recent announcements. Credit rating is unrated (likely because JSLL was SME-listed until August 2025, and RBI doesn’t mandate SME ratings).

Red Flag (as fact, not as sell signal): The shift from government business (₹118 Cr → ₹36 Cr YoY) suggests prior receivables pain. If government delayed payments or disputed invoices, that would explain the retreat. The company does not disclose the reason explicitly; inference is inference, not fact.

14. Industry Roast & Macro Context

The Ayurveda ecosystem remains ferociously fragmented. JSLL claims to be the leading organized player with ~11% of NABH-accredited Panchakarma clinics (50 of ~109) and 7% of NABH-accredited AYUSH hospitals (50 of ~291 estimated). That’s niche leadership in a niche category.

Macro winds are mixed. Yogi Adityanath’s UP Scheme (UPSS) and Ayushman-related programs are explicit government endorsements of Ayurveda as a cost-saving layer before allopathic surgery. If those schemes mature, JSLL’s 12 UP hospitals become hubs. Insurance companies are warming to Ayurveda as preventive pre-surgery intervention (JSLL’s insurance mix jumped 4% → 26% YoY)—that’s not macro tail-wind yet, but it’s momentum.

Counter-winds: Modern allopathy still dominates patient first-instinct. Ayurveda is seen as recovery or chronic-management, not acute care. If a patient has a heart attack or broken bone, they go to a hospital with ICU, not a Panchakarma clinic. JSLL’s model implicitly concedes this (it targets preventive, chronic, lifestyle-driven conditions). That segment is growing (India’s preventive healthcare spending is near-zero), but it’s niche.

Pricing wars are absent here (Ayurveda is not commoditized), but distribution wars are real. OTC retail is a new frontier—JSLL is launching products now, but established pharma chains (Apollo, Cipla, Lupin) could flood OTC shelves with ayurvedic products tomorrow. JSLL’s moat is customer lock-in via services (hospitals), not product differentiation (formulations are published in Ayurvedic texts).

15. EduInvesting Verdict

SWOT

Closing Line

A balance sheet with nothing to hide, a multiple with everything to prove: The company is executing a coherent flywheel (services → products → repeat), generating exceptional returns on capital (ROCE 70.7%), and translating that into cash flow (₹262 Cr operating cash, free cash positive). The market prices it at 34x earnings despite 178% earnings growth—a disconnect that resolves only if growth sustains. Occupancy at 51% versus break-even 35% is mathematically safe but operationally fragile; any sustained drop below 40% forces capex to turn destructive. The audit transition and Q4 one-time provisions muddy visibility on true run-rate margins (44% reported, 46% management-adjusted). Management’s ambition to hit ₹300 Cr PAT in FY27 (3x from FY26 in one year) is executable on paper (capacity + volume growth already visible), but each quarter will oscillate. Jeena Sikho is neither obvious nor impossible; it’s a bet on Ayurveda scaling as a preventive-health category while one founder’s brand holds the flywheel together. The next 12 months will tell whether that’s durability or luck.